Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-27T10:37:49.108Z Has data issue: false hasContentIssue false
  • English
  • Français

Intravenous paracetamol with a lower dose is also effective for the treatment of patent ductus arteriosus in pre-term infants

Published online by Cambridge University Press:  27 August 2014

Kadir Şerafettin Tekgündüz ,
Naci Ceviz ,
İbrahim Caner ,
Haşim Olgun ,
Yaşar Demirelli ,
Canan Yolcu ,
İrfan Oğuz Şahin  and
Mustafa Kara
Kadir Şerafettin Tekgündüz
Affiliation:
Division of Neonatology, Ataturk University Medical Faculty, Erzurum, Turkey
Naci Ceviz*
Affiliation:
Department of Pediatric Cardiology, Ataturk University Medical Faculty, Erzurum, Turkey
İbrahim Caner
Affiliation:
Division of Neonatology, Ataturk University Medical Faculty, Erzurum, Turkey
Haşim Olgun
Affiliation:
Department of Pediatric Cardiology, Ataturk University Medical Faculty, Erzurum, Turkey
Yaşar Demirelli
Affiliation:
Division of Neonatology, Ataturk University Medical Faculty, Erzurum, Turkey
Canan Yolcu
Affiliation:
Department of Pediatric Cardiology, Ataturk University Medical Faculty, Erzurum, Turkey
İrfan Oğuz Şahin
Affiliation:
Department of Pediatric Cardiology, Ataturk University Medical Faculty, Erzurum, Turkey
Mustafa Kara
Affiliation:
Division of Neonatology, Ataturk University Medical Faculty, Erzurum, Turkey
*
Correspondence to: N. Ceviz, Division of Pediatric Cardiology, Ataturk University Medical Faculty, Erzurum 25040, Turkey. Tel:+90 442 344 6990 Fax: +90 442 344 7696; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: Haemodynamically significant patent ductus arteriosus is a significant cause of morbidity and mortality in pre-term infants. This retrospective study was conducted to investigate the usefulness of lower-dose paracetamol for the treatment of patent ductus arteriosus in pre-term infants. Materials and Methods: A total of 13 pre-term infants who received intravenous paracetamol because of contrindications or side effects to oral ibuprofen were retrospectively enrolled. In the first patient, the dose regimen was 15 mg/kg/dose, every 6 hours. As the patient developed significant elevation in transaminase levels, the dose was decreased to 10 mg/kg/dose, every 8 hours in the following 12 patients. Echocardiographic examination was conducted daily. In case of closure, it was repeated after 2 days and when needed thereafter in terms of reopening. Results: A total of 13 patients received intravenous paracetamol. Median gestational age was 29 weeks ranging from 24 to 31 weeks and birth weight was 950 g ranging from 470 to 1390 g. The median postnatal age at the first intravenous paracetamol dose was 3 days ranging from 2 to 9 days. In 10 of the 13 patients (76.9%), patent ductus arteriosus was closed at the median 2nd day of intravenous paracetamol ranging from 1 to 4 days. When the patient who developed hepatotoxicity was eliminated, the closure rate was found to be 83.3% (10/12). Conclusion: Intravenous paracetamol may be a useful treatment option for the treatment of patent ductus arteriosus in pre-term infants with contrindication to ibuprofen. In our experience, lower-dose paracetamol is effective in closing the patent ductus arteriosus in 83.3% of the cases.

Keywords

Intravenousparacetamolpatent ductus arteriosuspremature infant
Type
Original Articles
Information
Cardiology in the Young , Volume 25 , Issue 6 , August 2015 , pp. 1060 - 1064
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Dani, C, Bertini, G, Corsini, I, et al. The fate of ductus arteriosus in infants at 23–27 weeks of gestation: from spontaneous closure to ibuprofen resistance. Acta Paediatr 2008; 97: 1176–1180.CrossRefGoogle ScholarPubMed
2. Van Overmeire, B, Chemtob, S. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 2005; 10: 177–184.CrossRefGoogle ScholarPubMed
3. Bose, CL, Laughon, MM. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 2007; 92: F498–F502.CrossRefGoogle ScholarPubMed
4. Chiruvolu, A, Jaleel, MA. Therapeutic management of patent ductus arteriosus. Early Hum Dev 2009; 85: 151–155.Google ScholarPubMed
5. Ohlsson, A, Walia, R, Shah, SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2013; 4: CD003481.Google Scholar
6. Ghanem, S, Mostafa, M, Shafee, M. Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. J Saudi Heart Assoc 2010; 22: 7–12.CrossRefGoogle ScholarPubMed
7. Hammerman, C, Bin-Nun, A, Markovitch, E, Schimmel, MS, Kaplan, M, Fink, D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics 2011; 128: 1618–1621.CrossRefGoogle ScholarPubMed
8. Oncel, MY, Yurttutan, S, Uras, N, et al. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed 2013; 98: F94.CrossRefGoogle ScholarPubMed
9. Yurttutan, S, Oncel, MY, Arayici, S, et al. A different first choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med 2013; 26: 825–827.CrossRefGoogle ScholarPubMed
10. Dang, D, Wang, D, Zhang, C, Zhou, W, Zhou, Q, Wu, H. Comparison of oral Paracetamol versus Ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One 2013; 8: e77888.CrossRefGoogle ScholarPubMed
11. Oncel, MY, Yurttutan, S, Erdeve, O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr 2013; 164: 510–514; e1.CrossRefGoogle ScholarPubMed
12. Sinha, R, Negi, V, Dalal, SS. An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol 2013; 2: 30–32.CrossRefGoogle ScholarPubMed
13. Ozdemir, OM, Doğan, M, Küçüktaşçı, K, Ergin, H, Sahin, O. Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation. Pediatr Cardiol 2013; 35: 276–279.CrossRefGoogle ScholarPubMed
14. Kessel, I, Waisman, D, Lavie-Nevo, K, Golzman, M, Lorber, A, Rotschild, A. Paracetamol effectiveness, safety and blood level monitoring during patent ductus arteriosus closure: a case series. J Matern Fetal Neonatal Med 2014, doi:10.3109/14767058.2013.871630.CrossRefGoogle ScholarPubMed
15. Jasani, B, Kabra, N, Nanavati, RN. Oral paracetamol in treatment of closure of patent ductus arteriosus in preterm neonates. J Postgrad Med 2013; 59: 312–314.CrossRefGoogle ScholarPubMed
16. Terrin, G, Conte, F, Scipione, A, et al. Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates. Ital J Pediatr 2014; 40(1): 21.CrossRefGoogle ScholarPubMed
17. Oncel, MY, Yurttutan, S, Degirmencioglu, H, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2012; 103: 166–169.CrossRefGoogle ScholarPubMed
18. Tekgunduz, KS, Ceviz, N, Demirelli, Y, et al. Intravenous paracetamol for patent ductus arteriosus in premature infants – a lower dose is also effective. Neonatology 2013; 104: 6–7.CrossRefGoogle ScholarPubMed
19. Gregory, KE, Deforge, CE, Natale, KM, Phillips, M, Van Marter, LJ. Necrotizing enterocolitis in the premature infant: neonatal nursing assessment, disease pathogenesis, and clinical presentation. Adv Neonatal Care 2011; 11: 155–164.CrossRefGoogle ScholarPubMed
20. Moore, TA, Wilson, ME. Feeding intolerance: a concept analysis. Adv Neonatal Care 2011; 11: 149–154.CrossRefGoogle ScholarPubMed
21. Anderson, BJ, Van Lingen, RA, Hansen, TG, et al. Acetaminophen developmental pharmacokinetics in premature neonates and infants. Anesthesiology 2002; 96: 1336–1345.CrossRefGoogle ScholarPubMed
22. Van Lingen, RA, Deinum, HT, Quak, JM, et al. Pharmacokinetics and metabolism of rectally administered paracetamol in preterm infants. Arch Dis Child Fetal Neonatal Ed 1999; 80: F59–F63.CrossRefGoogle Scholar
23. Allegaert, K, Van der Marel, CD, Debeer, A, et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed 2004; 89: F25–F28.CrossRefGoogle ScholarPubMed
24. Anderson, BJ. Paracetamol (acetaminophen): mechanisms of action. Paediatr Anaesth 2008; 18: 915–921.CrossRefGoogle ScholarPubMed
25. Aronoff, DM, Oates, JA, Boutaud, O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006; 79: 9–19.CrossRefGoogle ScholarPubMed
26. Allegaert, K, Anderson, B, Simons, S, van Overmeire, B. Paracetamol to induce ductus arteriosus closure: is it valid? Arch Dis Child 2013; 98: 462–466.CrossRefGoogle ScholarPubMed
27. Porta, R, Sánchez, L, Nicolás, M, García, C, Martínez, M. Lack of toxicity after paracetamol overdose in a extremely preterm neonate. Eur J Clin Pharmacol 2012; 68: 901–902.CrossRefGoogle Scholar
28. Allegaert, K, Anderson, BJ, Naulaers, G, et al. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. Eur J Clin Pharmacol 2004; 60: 191–197.CrossRefGoogle ScholarPubMed
29. Arana, A, Morton, NS, Hansen, TG. Treatment with paracetamol in infants. Acta Anaesthesiol Scand 2001; 45: 20–29.CrossRefGoogle ScholarPubMed
30. Palmer, GM, Atkins, M, Anderson, BJ, et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth 2008; 101: 523–530.CrossRefGoogle ScholarPubMed
31. Alan, S, Kahvecioglu, D, Erdeve, O, Atasay, B, Arsan, S. Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus? Neonatology 2013; 104: 168–169.CrossRefGoogle ScholarPubMed